CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Qualitas Consulting Group

Qualitas is a full-service consulting firm dedicated to quality results for our clients. We provide expert advice and technical support for business processes and tools, especially Contract Lifecycle Management (CLM) and Enterprise Legal Management (ELM) solutions. We are passionate about helping our clients achieve long‑lasting success, and we are proud to be a woman-owned business.

ODP Business Solutions

ODP Business Solutions, LLC, an operating company of The ODP Corporation (NASDAQ:ODP), is a leading B2B provider of workplace and technology solutions, combining an extensive range of products and services with a national footprint and hundreds of experienced business advisors. As a trusted partner, ODP Business Solutions supports over 120,000 corporate clients with navigating the often complex needs of todays business environment. From accessing comprehensive solutions and strategic alliances, to supply chain innovation and robust digital platforms, ODP Business Solutions helps customers achieve business results across every industry. #ODPBusinessSolutions #workplacesolutions #technologysolutions #B2Bprovider

Diamond Baseball Holdings

Diamond Baseball Holdings (DBH) is a New York-based company founded in 2021 that owns and operates a significant portfolio of Minor League Baseball (MiLB) clubs affiliated with Major League Baseball. The company focuses on professional management, best practices, and innovative investments to enhance fan experiences, brand engagement, player conditions, and community impact. As of 2024, DBH has acquired 33 teams, making it one of the largest ownership groups in MiLB history. The company emphasizes maintaining baseballs traditions while upgrading facilities and improving player welfare. DBH operates as part of Silver Lakes sports investments and applies private equity strategies to enhance operations and achieve market-beating returns. Its initiatives include partnerships for stadium upgrades and innovations aimed at boosting fan attendance and creating superior environments for both fans and players.

Honest1 Auto Care

Honest1, a national full-service auto care company, is passionate about putting customers first. Its customer-centric, transparent approach assures every customer is thoroughly educated on the systems and services necessary to keep their vehicles in the best running condition. Honest1 centers are family-friendly with clean and upscale waiting areas, Internet cafes, childrens play areas, comfortable leather chairs and couches, HDTVs and complimentary beverage stations. In addition to putting its customers first, Honest1 Auto Care performs H-1 ESA Quality checks at each of its locations to ensure performance is environmentally sustainable.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.